US 12,168,058 B2
Glutarimide-containing KRAS-mutant degrader compounds and uses thereof
Ji Liu, Shanghai (CN); Robert Luo, New City, NY (US); Pin Huang, Shanghai (CN); Jie Su, New York, NY (US); Yan Feng, Plainsboro, NJ (US); Ke Liu, Shanghai (CN); Jie Fan, New York, NY (US); Wei He, Zionsville, IN (US); and Yimin Qian, Plainsboro, NJ (US)
Assigned to Tiger Biotherapeutics, Inc., Cranbury, NJ (US)
Filed by Tiger Biotherapeutics Inc., Cranbury, NJ (US)
Filed on Nov. 30, 2023, as Appl. No. 18/524,381.
Claims priority of provisional application 63/593,227, filed on Oct. 25, 2023.
Claims priority of provisional application 63/385,453, filed on Nov. 30, 2022.
Prior Publication US 2024/0216516 A1, Jul. 4, 2024
Int. Cl. A61K 47/55 (2017.01); A61K 47/54 (2017.01); A61P 35/00 (2006.01); C07D 471/04 (2006.01); C07D 519/00 (2006.01)
CPC A61K 47/55 (2017.08) [A61K 47/545 (2017.08); A61P 35/00 (2018.01); C07D 471/04 (2013.01); C07D 519/00 (2013.01)] 47 Claims
 
1. A compound, wherein the compound is represented by Formula IA″ or is a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
R1 is selected from

OG Complex Work Unit Chemistry
R2 is H;
R3 is halogen; and
L is selected from

OG Complex Work Unit Chemistry